16 completed, 5 terminated, 2 recruiting, 2 unknown. 25 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 16, Terminated 5, Recruiting 2, Unknown 2 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Muscle Weakness: new trials by email Literature Review of Muscle Weakness trials Research Report on Muscle Weakness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy AAV9-Follistatin gene therapy, VEGF Plasmid - Age-related Muscle Decline | Phase 1 / Phase 2 | Recruiting | Unlimited Biotechnology LLC | 12 | 2026-06-01 | 2026-07-13 |
| Early Versus Conventional Cessation of Hydrocortisone in Septic Shock normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event | Phase 2 | Unknown | Mahidol University | 160 | 2023-07-05 | 2024-04-05 |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease KL1333, Placebo - Primary Mitochondrial Disease | Phase 2 | Recruiting | Pharming Technologies B.V. | 180 | 2022-12-13 | 2026-06-26 |
| Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection AXA1125, Placebo - Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Phase 2 | Completed | Axcella Health, Inc | 41 | 2021-12-15 | 2022-10-20 |
| Electrical Stimulation for Critically Ill Post-Covid-19 Patients Electrical Stimulation, Electrical Stimulation - Sham - COVID-19, Muscle Atrophy | Phase 2 | Completed | Baylor College of Medicine | 19 | 2021-08-18 | 2023-03-07 |
| A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy Bocidelpar, Placebo - Primary Mitochondrial Myopathy | Phase 2 | Terminated | Astellas Pharma Inc | 34 | 2021-05-24 | 2025-07-03 |
| Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) Hesperidin, Placebo - Covid19, Anosmia | Phase 2 | Completed | Montreal Heart Institute | 216 | 2021-02-18 | 2022-04-08 |
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency doxecitine and doxribtimine - Thymidine Kinase 2 Deficiency | Phase 2 | Completed | UCB BIOSCIENCES, Inc. | 47 | 2019-07-05 | 2026-09-08 |
| Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome Nicotinamide Riboside (NR) - Cancer, Skin Fibroblasts | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2019-03-25 | 2020-12-08 |
| Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction? Gabapentin, Tramadol, Panadol - Muscle Weakness, Anterior Cruciate Ligament Rupture | Phase 2 / Phase 3 | Unknown | Hospital Authority, Hong Kong | 30 | 2018-07-01 | 2018-04-12 |
| Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) GSK2881078, Matching Placebo - Cachexia | Phase 2 | Completed | GlaxoSmithKline | 97 | 2018-02-28 | 2020-07-15 |
| A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) BIO101, Placebo - Sarcopenia, Gait Disorders in Old Age | Phase 2 | Completed | Biophytis | 233 | 2017-02-07 | 2024-10-01 |
| Effect of PROGRESSive Training and Teststerone in Older Frail Men testosterone, Progressive muscle training - Muscle Weakness | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 192 | 2016-11-01 | 2024-05-29 |
| Evaluating Muscle Weakness Improvement With Lorcaserin in ICU Lorcaserin, Placebo - Muscle Weakness, Sepsis | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 5 | 2015-12-01 | 2020-01-13 |
| Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin - Chronic Obstructive Pulmonary Disease, Muscle Weakness | Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2014-04-16 | 2017-02-15 |
| Once-Daily Oral Dose of BeneFlax to Healthy Older Adults secoisolariciresinol diglucoside, vitamin D - Oxidative Stress, Inflammation | Phase 1 / Phase 2 | Completed | University of Saskatchewan | 32 | 2013-04-01 | 2018-06-14 |
| A Study in Older Participants Who Have Fallen and Have Muscle Weakness LY2495655, Placebo - Muscle Weakness | Phase 2 | Completed | Eli Lilly and Company | 201 | 2012-05-01 | 2018-04-25 |
| Oxidative Stress and Nutritional Supplementation Intervention Study secoisolariciresinol diglucoside - Oxidative Stress, Inflammation | Phase 2 | Completed | University of Saskatchewan | 21 | 2010-10-01 | 2018-10-25 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis BAF312, Placebo - Polymyositis, Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2010-06-15 | 2019-04-25 |
| Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Coenzyme Q10, Placebo - Pain, Weakness | Phase 2 / Phase 3 | Completed | Catherine Buettner | 68 | 2009-12-01 | 2017-01-23 |
Showing 20 of 25. Sign in to see all of them.
Pain (4) · Inflammation (3) · Muscular Atrophy (3) · Sarcopenia (3) · COVID-19 (2) · Dermatomyositis (2) · Fatigue (2) · Frailty (2) · Mitochondrial Diseases (2) · Myalgia (2) · Myositis, Inclusion Body (2) · Polymyositis (2) · Pulmonary Disease, Chronic Obstructive (2) · Abdominal Pain (1)
Musculoskeletal Diseases (25) · Nervous System Diseases (25) · Neurologic Manifestations (25) · Neuromuscular Manifestations (25) · Pathologic Processes (25) · Pathological Conditions, Signs and Symptoms (25) · Signs and Symptoms (25) · Muscular Diseases (24) · Atrophy (5) · Lung Diseases (5) · Neuromuscular Diseases (5) · Pathological Conditions, Anatomical (5) · Respiratory Tract Diseases (5) · Infections (4) · Metabolic Diseases (4)
Testosterone (2) · secoisolariciresinol diglucoside (2) · Acetaminophen (1) · Autogenic Training (1) · Cholecalciferol (1) · Deoxycytidine (1) · Ecdysterone (1) · Electric Stimulation (1) · GSK2881078 (1) · Gabapentin (1) · Geritol (1) · Growth Hormone (1) · Hesperidin (1) · Hydrocortisone (1) · Infliximab (1)
University of Saskatchewan (2) · Astellas Pharma Inc (1) · Axcella Health, Inc (1) · Baylor College of Medicine (1) · Biophytis (1) · Catherine Buettner (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Hospital Authority, Hong Kong (1) · Jeffrey A. Cohen, MD (1) · Johns Hopkins University (1) · Mahidol University (1) · Montreal Heart Institute (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
United States (17) · United Kingdom (4) · Canada (3) · Germany (3) · Australia (2) · Belgium (2) · Czechia (2) · Denmark (2) · France (2) · Spain (2) · Sweden (2) · Argentina (1) · Honduras (1) · Hungary (1) · Israel (1)
Adam I Schiffenbauer, M.D. (1) · Amel Karaa, MD (1) · Betty Raman, MBBS DPhil FRACP (1) · Catherine Buettner, MD, MPH (1) · Dale M Needham, MD, PhD (1) · Ellen F. Binder, MD (1) · Fred R. Sattler, MD (1) · Jane Alcorn, DVD, PhD (1) · Jeffrey A. Cohen, MD (1) · Jennifer Jones, MD, FRCPC (1) · Jocelyn Dupuis, MD (1) · Karsten Overgaard, M.D. (1) · Kerry Mansell, BSP, PharmD (1)
PMID 28159728, PMID 21543538, PMID 26516121, PMID 28922068, PMID 29174792, PMID 29500160, PMID 33246973, PMID 36283827, PMID 36905161, PMID 37223439, PMID 38641716, PMID 39289825
2008 (1), 2017 (1), 2018 (1), 2023 (1), K23AR055664 (1), P30CA016056 (1), P50CA090440 (1), R01AG018169 (1), UL1TR001079 (1)